Home › Research › Clinical trials
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Simon Scharf, Alastair G. Mander, A. Ugoni, Frank J.E. Vajda, N. Christophidis. Neurology, 1999-07-01
Topic: Drug trials: efficacy and safety
Plain-language summary
There were no group differences with any of the outcome measures in an intent-to-treat analysis. There were some nonsignificant trends for the placebo group to have deteriorated more than the D/M-treated patients. Withdrawal rates were 12 of 24 in the D/M group and 2 of 17 in the placebo group. There were no serious drug-related adverse events. This pilot study, with small treatment numbers, did not demonstrate a significant effect of NSAID treatment in AD, but the trends observed justify further investigations with a larger number of participants. D/M is safe in AD patients, but its tolerability is not optimal.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Scharf, S., Mander, A. G., Ugoni, A., Vajda, F. J., & Christophidis, N. (1999). A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. https://doi.org/10.1212/wnl.53.1.197
Vancouver
Scharf S, Mander AG, Ugoni A, Vajda FJ, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. 1999. doi:10.1212/wnl.53.1.197. PMID: 10408559.
BibTeX
@article{scharf1999-10408559,
author = {Scharf, Simon and Mander, Alastair G. and Ugoni, A. and Vajda, Frank J.E. and Christophidis, N.},
title = {{A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease}},
journal = {Neurology},
year = {1999},
doi = {10.1212/wnl.53.1.197},
pmid = {10408559},
url = {https://doi.org/10.1212/wnl.53.1.197}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- There were no group differences with any of the outcome measures in an intent-to-treat analysis.
- There were some nonsignificant trends for the placebo group to have deteriorated more than the D/M-treated patients.
- Withdrawal rates were 12 of 24 in the D/M group and 2 of 17 in the placebo group.
- There were no serious drug-related adverse events.
- This pilot study, with small treatment numbers, did not demonstrate a significant effect of NSAID treatment in AD, but the trends observed justify further investigations with a larger number of participants.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Participants41
- Evidence strengthHigh
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design and effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 32 of the 58 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1999 — older than 20 years, still counted |
| Sample size | 1 / 4 | 41 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 10408559) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 32 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 58 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical trials from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.